CSBR - Champions Oncology, Inc.
| Previous Close | 7.65 |
| Open | 7.65 |
| Bid | 0.00 x 2900 |
| Ask | 13.00 x 1200 |
| Day's Range | 7.65 - 7.65 |
| 52 Week Range | 6.86 - 17.90 |
| Volume | 539 |
| Avg. Volume | 30,175 |
| Market Cap | 88.857M |
| Beta (3Y Monthly) | 2.43 |
| PE Ratio (TTM) | 765.00 |
| EPS (TTM) | 0.01 |
| Earnings Date | Jul 24, 2019 - Jul 29, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.33 |
- ACCESSWIRE•2 days ago
Champions Oncology Reports Record Quarterly Revenue of $7.7 Million For The Fourth Quarter Ended April 30, 2019
Record Annual Revenue of $27 Million HACKENSACK, NJ / ACCESSWIRE / July 15, 2019 / Champions Oncology, Inc. (NASDAQ: CSBR), engaged in the development of advanced technology solutions and services to personalize ...
- ACCESSWIRE•5 days ago
Champions Oncology to Announce Fourth Quarter Financial Results on Monday, July 15, 2019
HACKENSACK, NJ / ACCESSWIRE / July 12, 2019 / Champions Oncology, Inc. (CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced it will report its financial and operational results for the fourth quarter ended April 30, 2019, on Monday, July 15, 2019, after market close. The company will host a conference call to discuss the results that day at 4:30 p.m. EST (1:30 p.m. PST). A replay of the call will be available by dialing 877-481-4010 and entering Passcode: 50412, or by accessing the Investor tab of the company's website within 72 hours.
- Simply Wall St.•15 days ago
Calculating The Intrinsic Value Of Champions Oncology, Inc. (NASDAQ:CSBR)
Today we will run through one way of estimating the intrinsic value of Champions Oncology, Inc. (NASDAQ:CSBR) by...
- Simply Wall St.•2 months ago
How Many Champions Oncology, Inc. (NASDAQ:CSBR) Shares Have Insiders Sold, In The Last Year?
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
- ACCESSWIRE•2 months ago
Champions Oncology Partners with TransCure bioServices to Expand European Business and Operations
HACKENSACK, NJ / ACCESSWIRE / May 30, 2019 / Champions Oncology, Inc. (CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced they have partnered with TransCure bioServices to expand the pharmacology operations of Champions' translational oncology tools throughout Europe. Champions' European customers can continue their unique and consultative interactions with the Champions business development and project leadership teams, along with the option of performing the pharmacology work locally. An operations solution in Europe reduces the intercontinental logistics involved with performing the work in the US.
- Simply Wall St.•3 months ago
What Kind Of Shareholder Owns Most Champions Oncology, Inc. (NASDAQ:CSBR) Stock?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Every investor in Champions Oncology, Inc. (NASDAQ:CSBR) should be aware of the most powerful shareho...
- Zacks•3 months ago
Moving Average Crossover Alert: Champions Oncology
Champions Oncology, Inc. (CSBR) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
- Zacks•3 months ago
New Strong Sell Stocks for April 16th
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today
- Zacks•4 months ago
New Strong Sell Stocks for April 1st
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today
- Zacks•4 months ago
New Strong Sell Stocks for March 27th
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today:
- ACCESSWIRE•4 months ago
Champions Oncology Reports Quarterly Revenue of $6.4 Million
Reiterates Expectations for Revenue Growth of at Least 20% for Fiscal Year 2019 HACKENSACK, NJ / ACCESSWIRE / March 18, 2019 / Champions Oncology, Inc. (NASDAQ: CSBR), engaged in an end-to-end range of ...
- ACCESSWIRE•4 months ago
Champions Oncology to Announce Third Quarter Financial Results on Monday, March 18, 2019
HACKENSACK, NJ / ACCESSWIRE / March 6, 2019 / Champions Oncology, Inc. (NASDAQ: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development ...
- Zacks•4 months ago
Champions Oncology (CSBR) Q3 Earnings: What's in Store?
During Champions Oncology's (CSBR) third-quarter fiscal 2019 conference call, investor focus will be on the company's progress with its Ex Vivo platform and services.
- Zacks•6 months ago
Weakness Seen in Champions Oncology (CSBR) Estimates: Should You Stay Away?
Champions Oncology (CSBR) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
- ACCESSWIRE•7 months ago
Champions Oncology Participates in Pre-Clinical Studies to Identify Novel Therapy for Childhood Cancer
HACKENSACK, NJ / ACCESSWIRE / December 17, 2018 / Champions Oncology, Inc. (CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced, in partnership with Drs. Narendra Bharathy and Charles Keller at the Children's Cancer Therapy Development Institute (cc-TDI), the publication of in-vivo oncology pharmacology data presenting the effectiveness of the investigational drug entinostat in Patient Derived Xenograft (PDX) models of Pediatric Rhabdomyosarcoma. The data, published in Science Signaling (http://stke.sciencemag.org/content/11/557/eaau7632.editor-summary) demonstrates the advantages of utilizing well-selected PDX models in pre-clinical drug development and helped confirm the earlier research performed by Drs. Bharathy and Keller at cc-TDI.
- ACCESSWIRE•7 months ago
Champions Oncology Reports Quarterly Revenue of $6.7 Million
Reiterates Expectations for Revenue Growth of at Least 20% for Fiscal Year 2019 HACKENSACK, NJ / ACCESSWIRE / December 17, 2018 / Champions Oncology, Inc. (NASDAQ: CSBR), engaged in an end-to-end range ...
- PR Newswire•7 months ago
Champions Oncology to Announce Second Quarter Financial Results on Monday, December 17, 2018
HACKENSACK, N.J., Dec. 10, 2018 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced it will report its financial and operational results for the second quarter ended October 31, 2018, on Monday, December 17, 2018. The company will host a conference call to discuss the second quarter results that day at 4:30 p.m. EST (1:30 p.m. PST). A replay of the call will be available by dialing 877-481-4010 or 919-882-2331 and entering Passcode: 41544, or by accessing the Investor tab of the company's website within 72 hours.
- Zacks•8 months ago
Champions Oncology (CSBR) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Champions Oncology (CSBR) closed at $10.39, marking a +0.39% move from the previous day.
- GlobeNewswire•8 months ago
Analysis: Positioning to Benefit within Red Lion Hotels, P.A.M. Transportation Services, Champions Oncology, Kingstone Companies, Applied DNA Sciences, and Innodata — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Nov. 15, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- PR Newswire•8 months ago
Champions Oncology to Participate in the 9th Annual Craig-Hallum Alpha Select Conference
HACKENSACK, N.J., Nov. 7, 2018 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced that management, will participate in the 9th annual Craig-Hallum Alpha Select conference on Thursday, November 15, 2018, in New York. For more information about the conference or to schedule a one-on-one meeting with management, please contact your Craig Hallum representative or Hayden IR at james@haydenir.com. Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs.
- Zacks•8 months ago
Champions Oncology Sees Hammer Chart Pattern: Time to Buy?
Champions Oncology has been struggling lately, but the selling pressure may be coming to an end soon.
- Zacks•9 months ago
Has Champions Oncology (CSBR) Outpaced Other Medical Stocks This Year?
Is (CSBR) Outperforming Other Medical Stocks This Year?
- Zacks•9 months ago
Champions Oncology (CSBR) Gains As Market Dips: What You Should Know
Champions Oncology (CSBR) closed at $12.21 in the latest trading session, marking a +0.58% move from the prior day.
- Zacks•9 months ago
Bull Of The Day: Champions Oncology (CSBR)
Bull Of The Day: Champions Oncology (CSBR)
